Description
• রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন।
Indications:
Treatment of type 2 diabetes mellitus to improve glycemic control, especially when monotherapy is insufficient.
Pharmacology:
Empagliflozin inhibits SGLT2 in the kidneys reducing glucose reabsorption. Linagliptin is a DPP-4 inhibitor that increases insulin release and decreases glucagon levels.
Dosage:
One tablet once daily, with or without food, dose adjusted by physician.
Administration:
Oral administration; swallow whole with water.
Interaction:
May interact with other antidiabetic drugs, diuretics, and insulin.
Contraindications:
Type 1 diabetes, ketoacidosis, hypersensitivity to components.
Side Effects:
Urinary tract infections, hypoglycemia, headache, nasopharyngitis.
Pregnancy & Lactation:
Use only if clearly needed and under medical supervision.
Precautions & Warnings:
Monitor kidney function and blood glucose regularly.
Therapeutic Class:
SGLT2 inhibitor and DPP-4 inhibitor combination
Storage Conditions:
Store below 30°C, in a dry place away from light.
Change Language